In early 2020, Justin Fulcher was back in Charleston, South Carolina after helping oversee RingMD’s transition from Singapore to Boston. He had spent roughly a year assisting the handover after selling the company in 2018, and the platform had relaunched in the United States in 2019. Within weeks of his return, COVID-19 arrived and changed every assumption the healthcare industry had made about the pace of digital adoption.

Free Access in a Crisis

Fulcher’s response was direct. He offered a white-labelled version of the RingMD platform free of charge to doctors, hospitals, and healthcare organizations worldwide. The logic was consistent with the one that had shaped the company from the beginning: lower the barrier enough, and people will use it. The pandemic removed what had previously been the primary friction point institutional reluctance to treat virtual care as a legitimate substitute for in-person visits.

“COVID has taken telemedicine and digital healthcare from a nice-to-have to a must-have,” Fulcher said at the time. That shift, while sudden from the outside, reflected dynamics that RingMD had been navigating for years. Building in markets where healthcare infrastructure was absent had already required the platform to prove its value without the benefit of entrenched institutional support.

The broader pivot Fulcher had engineered before the pandemic positioned RingMD well for the moment. The consumer-facing marketplace approach that defined the Singapore era had been replaced by a government-focused, compliance-first platform built for regulated environments. By 2020, RingMD held FedRAMP Moderate, FISMA, and HIPAA compliance certifications. The infrastructure was designed for rural connectivity and low-bandwidth conditions a technical specification that matched both the government client base and the pandemic’s sudden demand for reach.

Justin Fulcher had described the 2018 sale not as an exit but as a move to scale. COVID made that framing visible. When the crisis arrived, the platform was already built for the conditions it would need to perform in. Read this article for related information.

Learn more about Judd Zebersky on https://x.com/JustinFulcher